Related by context. All words. (Click for frequent words.) 78 refractory chronic myeloid 71 leukemia CML 67 imatinib resistant 67 chronic myeloid leukemia CML 66 Gleevec resistant 66 imatinib Gleevec ® 65 refractory ovarian cancer 64 depression TRD 64 Chronic Myelogenous Leukemia CML 64 Ph + acute lymphoblastic 64 chronic myeloid 63 T#I mutant 63 cytogenetic responses 63 Helicobacter pylori H. pylori 63 HIV Lalezari 63 chronic myelogenous leukemia CML 63 imatinib Gleevec 63 nilotinib 62 KRAS mutant tumors 62 indolent NHL 62 gastrointestinal stromal tumors GIST 62 hypereosinophilic syndrome 62 leukemia AML 62 refractory SCLC 62 T#I [002] 62 TKI therapy 62 Streptococcus pneumonia 62 T#I mutation 62 heavily pretreated 62 rituximab Rituxan 61 cisplatin chemotherapy 61 dasatinib Sprycel ® 61 Epratuzumab 61 GBM tumors 61 nucleoside analogs 61 leukemia ALL 61 antibiotic methicillin 61 dasatinib Sprycel 61 tyrosine kinase inhibitors TKIs 61 Naive Patients 61 erlotinib Tarceva ® 61 recurrent glioblastoma multiforme 60 Ph + ALL 60 Isentress raltegravir 60 panitumumab Vectibix 60 hepatitis C genotype 60 metastatic renal cell carcinoma 60 prostate cancer mCRPC 60 S. aureus isolates 60 eosinophilic asthma 60 hormone deprivation 60 KRAS wild 60 basiliximab 60 gastrointestinal stromal tumor GIST 60 mutated KRAS 60 mutated KRAS gene 60 Myelodysplastic Syndrome MDS 60 chronic lymphocytic leukemia CLL 60 Dasatinib 60 Ribavirin causes 60 discontinued Viread 60 nucleoside analogues 60 cilengitide 60 neuroblastoma tumors 60 thalidomide Thalomid 60 relapsed MM 59 atypical hemolytic uremic syndrome 59 evaluating tivozanib 59 Gleevec imatinib mesylate 59 metastatic malignant melanoma 59 dasatinib 59 Glioblastoma multiforme GBM 59 Acute myeloid leukemia 59 CYT# potent vascular disrupting 59 heavily pretreated patients 59 CML CP 59 KRAS mutations occur 59 imatinib resistance 59 Rituxan rituximab 59 cidofovir 59 nucleotide analog 59 Epstein Barr virus EBV 59 BARACLUDE ® 59 HER2 overexpression 59 sunitinib Sutent ® 59 lenalidomide Revlimid R 59 relapsed refractory 59 leukemia CLL 59 Ph + 59 chlorambucil 59 erlotinib Tarceva 59 anti EGFR antibody 59 Glioblastoma Multiforme 59 alkylating agent 59 Fludarabine 59 myelofibrosis polycythemia vera 59 Anthracycline 59 HBeAg positive 59 Chronic Lymphocytic Leukemia CLL 59 nilotinib Tasigna ® 59 AMN# [001] 59 basal cell nevus syndrome 59 rituximab refractory 59 SNT-MC#/idebenone 59 nonsmall cell lung cancer 59 decompensated liver disease 58 Bcr Abl mutations 58 patients evaluable 58 DFMO 58 pegylated liposomal doxorubicin 58 BRAF V#E 58 leukaemias 58 imatinib therapy 58 Staphylococcus aureus infections 58 anthracycline taxane 58 murine leukemia virus 58 CCR5 tropic 58 chronic HCV 58 Camptosar ® 58 metastatic malignant 58 Elotuzumab 58 bacterium Neisseria meningitidis 58 Waldenstrom macroglobulinemia 58 EGFR TKI 58 arsenic trioxide 58 K ras mutations 58 doxorubicin Adriamycin 58 meropenem 58 superficial bladder cancer 58 Toxicities 58 GIST tumors 58 VZV 58 recurrent genital herpes 58 adalimumab Humira 58 DLBCL 58 refractory Hodgkin 58 conventional chemotherapies 58 cutaneous T 58 Cryptococcus neoformans 58 pemphigus vulgaris 58 mycobacterium tuberculosis 58 kidney urologic 58 relapsed ovarian cancer 58 type 1diabetes 58 acinetobacter 58 HCV antibody 58 pneumococci 58 Leukemias 58 Alemtuzumab 58 bendamustine 58 Zolinza 58 uric acid lowering 58 Enbrel Humira 58 autoantibody positive 58 pentamidine 58 Hepatocellular Carcinoma HCC 58 radiation chemoradiation 58 squamous cell lung cancer 58 recurrent glioblastoma multiforme GBM 58 cisplatin resistant 58 chimeric monoclonal antibody 58 MAGE A3 ASCI 58 achieve sustained virologic 58 nutlin 3a 58 vWF 58 samalizumab 58 CHOP chemotherapy 58 hepatitis C HCV 58 BRAF V# mutation 58 PCNSL 58 efavirenz Sustiva 58 galiximab 58 Kit CD# positive 58 tigecycline 58 NRTI resistance 58 MGd 58 PKC# 58 XDR tuberculosis 58 gemifloxacin 58 Enterobacter cloacae 58 ritonavir boosted 57 Glioblastoma Multiforme GBM 57 Cutaneous T 57 epithelial tumors 57 chlamydial infections 57 Philadelphia Chromosome Positive 57 varicella zoster virus VZV 57 flavopiridol 57 nonmelanoma skin cancers 57 osteosarcomas 57 gemcitabine Gemzar 57 WNV encephalitis 57 OHR/AVR# 57 follicular lymphomas 57 pegylated interferon alpha 57 CMV infections 57 PROSTVAC VF 57 Chronic Myeloid Leukemia 57 Pemetrexed 57 bacteria Neisseria meningitidis 57 neuroendocrine cancers 57 immunized monkeys 57 Platinol ® cisplatin 57 bacterium Mycobacterium tuberculosis 57 Crizotinib 57 Gleevec imatinib 57 interferon ribavirin 57 achieved sustained virologic 57 papillary renal cell carcinoma 57 Chronic lymphocytic leukemia 57 metastatic renal cell 57 relapsed Acute Myeloid 57 lung cancer NSCLC 57 TTR amyloidosis 57 tinidazole 57 intravenous bisphosphonates 57 familial ALS 57 complete cytogenetic 57 SOD1 gene 57 platinum refractory 57 VFEND 57 idarubicin 57 metastatic RCC 57 basal cell carcinoma BCC 57 Arranon 57 Omacetaxine 57 antiretroviral naive 57 anthracycline containing 57 SCCHN 57 irinotecan chemotherapy 57 herpes zoster shingles 57 chemo radiotherapy 57 investigational monoclonal antibody 57 sorafenib Nexavar ® 57 Idiopathic Pulmonary Fibrosis IPF 57 Maribavir 57 squamous cell carcinoma SCC 57 Pegylated Interferon 57 trastuzumab resistant 57 mycophenolate mofetil 57 SPRYCEL ® 57 anterior uveitis 57 gastrointestinal stromal tumors GISTs 57 BRAF mutation 57 refractory CLL 57 ethambutol 57 FUSILEV enhances 57 smoldering myeloma 57 gastrointestinal stromal tumors 57 NOMID 57 transgenic rats 57 GRNOPC1 contains 57 refractory gout 57 aflibercept VEGF Trap 57 Paraplatin ® carboplatin 57 AEG# 57 herpes zoster virus 57 progressive PsA 57 malignant pleural mesothelioma 57 multidrug resistant 57 mapatumumab 57 antibiotic vancomycin 57 standard chemotherapy regimen 57 stage IIIB IV 57 relapsing remitting MS RRMS 57 gastrointestinal stromal tumor 57 lymphoid blast 57 taxane therapy 57 psoriatic arthritis PsA 57 Epidermal Growth Factor Receptor 57 PegIFN RBV 57 tyrosine kinase inhibitors 57 β lactam 57 Tarceva TM 56 lupus nephritis 56 huC# DM4 56 viral subtypes 56 FVIII inhibitors 56 FOLFOX chemotherapy 56 Noxafil 56 sulfamethoxazole 56 Talabostat 56 protease inhibitor PI 56 AZT zidovudine Retrovir 56 Nilotinib 56 cetuximab Erbitux ® 56 metastatic kidney 56 latent tuberculosis 56 gefitinib Iressa 56 docetaxel chemotherapy 56 parainfluenza virus 56 Candida infection 56 HBeAg negative 56 Relapsed Refractory 56 HBsAg 56 refractory NSCLC 56 phase IIb study 56 ZOLINZA 56 tipranavir ritonavir 56 systemic lupus erythematosus SLE 56 imipenem 56 investigational protease inhibitor 56 imatinib 56 PegIntron 56 trastuzumab Herceptin R 56 immunosuppressed patients 56 lymphoid malignancies 56 Salmonella Typhi 56 Follicular lymphoma 56 pan HDAC inhibitor 56 investigational integrase inhibitor 56 Sudhir Agrawal D.Phil 56 pancreatic adenocarcinoma 56 nucleoside naive 56 EGFR mutation positive 56 CCyR 56 paclitaxel Taxol ® 56 treatment naïve genotype 56 methicillin resistant MRSA 56 CANCIDAS 56 acute myelogenous leukemia AML 56 metastatic lung cancer 56 chronic GVHD 56 melanoma tumors 56 bacteria Pseudomonas aeruginosa 56 coagulase negative staphylococci 56 S. aureus infections 56 visilizumab 56 cutaneous T cell 56 mitoxantrone plus 56 HER2 positive cancers 56 BCR ABL inhibitors 56 H. influenzae 56 indolent follicular non 56 Amgen Neulasta R 56 candidemia 56 TRAIL induced apoptosis 56 Epivir 56 pneumocystis 56 Paraplatin ® 56 seminoma 56 BRAF V#E mutation 56 cabazitaxel 56 canakinumab 56 ano genital warts 56 taxane chemotherapy 56 Latent TB 56 immune suppressing 56 cetuximab Erbitux R 56 overexpress HER2 56 ponatinib 56 USA# strain 56 Diffuse Large B 56 fludarabine 56 pediatric acute lymphoblastic 56 invasive fungal infection 56 refractory metastatic 56 MenACWY 56 cytomegalovirus retinitis 56 amoxicillin clavulanate 56 antibody MAb 56 chronic HBV 56 mitoxantrone chemotherapy 56 Temsirolimus 56 HBeAg positive patients 56 bortezomib Velcade 56 micafungin 56 Aflibercept 56 metastatic colorectal 56 AVASTIN 56 multidrug resistance 56 oral antiviral 56 nilotinib Tasigna 56 Irinotecan 56 cyclophosphamide methotrexate 56 MCyR 56 relapsed leukemia 56 medically inoperable 56 INSPIRE Trial Phase III 56 immune modulatory 56 glioblastoma tumors 56 dual tropic 56 GISTs 56 lymphocytic leukemia 56 HCV infection 56 humanised monoclonal antibody 56 CCR5 receptor antagonist 56 Newly Diagnosed Multiple Myeloma 56 Refractory Hodgkin Lymphoma 56 nonvaccine 56 primary immunodeficiency PI 56 Velcade bortezomib 56 chronic plaque psoriasis 56 alefacept 56 Riluzole 56 raltegravir 56 genital herpes infections 56 Rimantadine 56 tenofovir Viread 56 treatment naive genotype 56 relapsed CLL 56 oral prodrug 56 bevacizumab Avastin 56 pomalidomide 56 Infusion reactions 56 interferon gamma 1b 56 systemic ALCL 56 recurrent ovarian cancer 56 progressive psoriatic arthritis 56 tyrosine kinase inhibitor 56 hepatocellular carcinomas 56 adriamycin 56 Non Hodgkin 56 indolent lymphoma 55 operable breast cancer 55 hemorrhagic fever viruses 55 attach auristatin 55 APTIVUS r 55 Chronic Myeloid Leukemia CML 55 K#N 55 daunorubicin 55 HCV infected 55 Ph + CML 55 serotype #A 55 complete remissions 55 KRAS mutant 55 S/GSK# 55 stage IIIb 55 Cell Lymphoma 55 MyVax R 55 idiopathic pulmonary fibrosis IPF 55 Opportunistic infections 55 baminercept 55 trastuzumab Herceptin ® 55 methicillin resistant S. aureus 55 DEB# 55 Chronic Myelogenous Leukemia 55 myeloid leukemia 55 HER2/neu 55 Novartis Gleevec 55 brain tumor glioblastoma 55 tumors GIST 55 thymidylate synthase 55 recurrent glioma 55 cell lymphoma CTCL 55 HERCEPTIN 55 EGFR inhibitors 55 chronic eosinophilic leukemia 55 Traficet EN 55 PTLD 55 pemetrexed Alimta 55 myeloproliferative neoplasms MPNs 55 estramustine 55 NNRTIs 55 dexrazoxane 55 varicella chickenpox 55 Thiovir 55 glioblastoma multiforme GBM 55 sodium stibogluconate 55 Myelofibrosis 55 alfa 2a 55 Advanced Melanoma 55 nasopharyngeal cancer 55 cyclophosphamide doxorubicin vincristine 55 interferon IFN 55 trabectedin 55 complete cytogenetic response 55 commonly infect humans 55 brain tumor glioblastoma multiforme 55 nonnucleoside reverse transcriptase inhibitors 55 docetaxel Taxotere 55 TET2 55 CLL SLL 55 S.aureus 55 Gemzar ® 55 EGFRvIII 55 peginterferon alfa 55 Folfox 55 hematological malignancy 55 immunodeficient 55 methicillin sensitive 55 rifamycins 55 myeloid 55 mTOR inhibitors 55 follicular Non Hodgkin 55 lymphocytic choriomeningitis virus LCMV 55 CLL cells 55 tyrosine kinase inhibitor TKI 55 CCR5 mAb 55 follicular lymphoma 55 Fludara ® 55 vinca alkaloid 55 receiving immunosuppressive therapy 55 medulloblastoma tumors 55 relapsing remitting 55 TB bacillus 55 multidrug resistant MDR 55 ceftriaxone 55 dermatofibrosarcoma protuberans 55 ADPKD 55 de novo kidney transplant 55 refractory chronic lymphocytic 55 parasite Plasmodium falciparum 55 Smac mimetic 55 Sutent sunitinib 55 huN# DM1 55 heterozygous FH 55 vaccine serotypes 55 Malignant Melanoma 55 Bloodstream infections 55 EGFR antibodies 55 Carboplatin 55 invasive candidiasis 55 DMARDS 55 antiestrogen 55 biliary tract cancer 55 ImmunoVEX HSV2 55 immunomodulator 55 Vincristine 55 Degarelix 55 decitabine 55 fluconazole resistant 55 shingles herpes zoster 55 chronic HCV infection 55 doublet chemotherapy 55 TB bacilli 55 small lymphocytic lymphoma 55 rhinovirus infections 55 Vidaza azacitidine 55 #I TM# 55 chronic myelogenous leukemia 55 idiopathic thrombocytopenic purpura ITP 55 Chronic myeloid leukemia 55 antiretroviral naïve 55 hA# 55 Sustiva efavirenz 55 immunosuppressives 55 acute myeloid 55 de novo AML 55 WNV infection 55 bleomycin 55 T. pallidum 55 HQK 55 myeloablative 55 BARACLUDE R 55 H. pylori eradication 55 mycobacterial infections 55 multidrug resistant strains 55 necrotizing pneumonia 55 Escherichia coli Klebsiella pneumoniae 55 staphylococcal infections 55 Proleukin 55 bevacizumab Avastin ® 55 Acute myelogenous leukemia 55 refractory acute myeloid 55 diabetic kidney 55 cytotoxin 55 rituximab 55 vancomycin resistant Enterococcus faecium 55 Adenoviral 55 cell acute lymphoblastic 55 pegylated interferon alfa 2a 55 anti CD3 antibody 55 acute promyelocytic leukemia 55 chronic HCV genotype 55 HCV genotype 1 55 CCR5 antagonist 55 Intelence 55 receptor tyrosine kinase inhibitor 55 imatinib mesylate Gleevec 55 haematologic 55 Enzastaurin 55 dose escalation phase 55 BRAF mutations 55 varicella infection 55 CCR5 tropic HIV 55 Adefovir 55 LY# [003] 55 P. falciparum parasite 55 renal toxicity 55 peginterferon alpha 2a 55 MabThera Rituxan 55 achieved sustained virological 55 diabetic peripheral neuropathy DPN 55 NS#/#A protease 55 HGS ETR1 55 weekly intravenous infusions 55 Hodgkin lymphoma HL 55 acute myeloid leukemia AML 55 NNRTI resistant 55 HBeAg negative patients 55 myelogenous leukemia 55 receptor inhibitor 55 denileukin diftitox 55 Cholangiocarcinoma 55 anti leukemic 55 HCV genotypes 55 carbapenem resistant 55 anthracyclines taxanes 55 vismodegib 55 benign prostatic hypertrophy BPH 55 MALT lymphoma 55 lichen planus 55 protease inhibitors PIs 55 partial remissions 55 metastatic GIST 55 BCR ABL mutations 55 BRAF gene 55 Bcr Abl T#I mutation 55 syngeneic 55 paralytic polio 55 TTR gene 55 NRTIs 55 organ transplant rejection 55 dexamethasone Decadron 55 forodesine 55 Boceprevir 55 FLT3 55 Acute Myelogenous Leukemia 55 Aptivus ® 55 genotype 1b 55 fistulizing Crohn disease 55 EGFR mutation 55 Jevtana 55 rituximab Rituxan ® 55 reverse transcriptase inhibitors 55 HNSCC 55 doxorubicin cyclophosphamide 55 lymphocytosis 55 parainfluenza 55 combination antiretroviral therapy 55 Fluconazole 55 Live Attenuated Influenza Vaccine 54 rilonacept 54 NRTI 54 seropositive patients 54 infliximab Remicade 54 mRCC 54 Rituximab 54 Recombinant interferon alpha 54 omalizumab 54 ulcerative colitis UC 54 Pneumocystis carinii pneumonia 54 antibiotics ciprofloxacin 54 immunized mice 54 MELAS 54 allogeneic bone marrow 54 cytogenetic response 54 potent antiviral 54 Reverset 54 renal flares 54 multiple sclerosis psoriasis 54 TMS Therapy 54 Interferon alpha 54 docetaxel Taxotere ® 54 Amantadine 54 Quinamed 54 griseofulvin 54 HAART regimen 54 immune thrombocytopenic purpura ITP 54 S. Typhi 54 adverse cytogenetics 54 doripenem 54 ZACTIMA 54 allogeneic stem cell 54 Histoplasma capsulatum 54 etanercept Enbrel 54 cisplatin gemcitabine 54 lymphoma CTCL 54 dapsone 54 Staphylococcus aureus bacteria 54 immunocompetent 54 Acute Myeloid Leukemia AML 54 ER CHOP 54 non nucleoside inhibitor 54 Hodgkin lymphoma NHL 54 TB bacterium 54 Chronic lymphocytic leukemia CLL 54 pegfilgrastim 54 ToGA 54 indinavir 54 ALK inhibitors 54 evaluable subjects 54 Carcinoid tumors 54 endometrial hyperplasia 54 chemotherapy cisplatin 54 Neuvenge 54 TNFalpha 54 fluoroquinolone resistant 54 recurrent NSCLC 54 virologically 54 adeno associated viruses 54 AZT zidovudine 54 HCV replicon 54 Paroxysmal Nocturnal Hemoglobinuria PNH 54 oblimersen 54 FOLFIRI alone 54 advanced metastatic renal 54 Pertuzumab 54 S Typhi 54 macrolide antibiotic 54 Genentech Rituxan 54 lung metastases 54 leukemia APL 54 pertuzumab 54 aprepitant 54 paclitaxel cisplatin 54 receiving TNF blockers 54 Panton Valentine Leukocidin PVL 54 peritoneal carcinomatosis 54 posterior uveitis 54 recurrent malignant glioma 54 ribavirin RBV 54 Rheumatoid Arthritis RA 54 Immune reconstitution syndrome 54 Crohn disease CD 54 hematological cancers 54 Helicobacter pylori eradication 54 inherited gene mutation 54 disease modifying antirheumatic 54 serous ovarian cancer 54 HCV nucleoside 54 Tumor Necrosis Factor 54 acyclovir Zovirax 54 TNF alpha antagonist 54 E. faecalis 54 dosing cohorts 54 refractory AML 54 immune thrombocytopenic purpura 54 esophageal candidiasis 54 Xelox 54 receiving highly emetogenic 54 DOXIL ® 54 naive HCV 54 metastatic neuroendocrine tumors 54 demonstrated antitumor activity 54 stage IIIb IV 54 anti angiogenic agents 54 acute GvHD 54 pulmonary hypertension PH 54 HBV vaccine 54 lamivudine resistant 54 Pharmacokinetics PK 54 ganciclovir 54 metaglidasen 54 familial pancreatic cancer 54 gemcitabine cisplatin 54 oral antifungal 54 mycosis fungoides 54 KRAS oncogene 54 Romidepsin 54 strep bacteria 54 nucleotide analogue 54 Acute lymphoblastic leukemia 54 cyclophosphamide Cytoxan 54 IMA# 54 beta lactam antibiotic 54 temozolomide Temodar 54 neuroblastomas 54 CD#c 54 Eculizumab 54 cSSSIs 54 gemcitabine carboplatin 54 myeloproliferative disorders 54 Paxil paroxetine 54 naive HCV genotype 54 lumiliximab 54 Protease inhibitors 54 PCV7 vaccine 54 cytokine refractory 54 S. suis 54 oral vancomycin 54 Nitazoxanide 54 ixabepilone 54 Alequel 54 LC#m# vaccine 54 Triapine 54 ifosfamide 54 paclitaxel Taxol R 54 Hepatitis C virus HCV 54 EGFR pathway 54 Interferon Beta 54 CD# mAb 54 CMV infection 54 diagnosed Ph + 54 LymphoStat B belimumab 54 KRAS mutations 54 chronic HBV infection 54 ketolide antibiotic 54 paricalcitol 54 medullary thyroid cancer 54 Pegasys ® 54 relapsed AML 54 pharmacokinetic interactions 54 proteasome inhibitor 54 pyrazinamide 54 degenerative retinal diseases 54 Protease inhibitor 54 infliximab 54 breast carcinomas 54 milatuzumab 54 P. acnes 54 EGFR tyrosine kinase inhibitors 54 steroid refractory GvHD 54 hormone receptor negative 54 angiogenesis inhibitor 54 Fludara 54 transcriptase inhibitors 54 advanced medullary thyroid 54 non hodgkin lymphoma 54 Fluorouracil 54 alkylating agents 54 transthyretin amyloidosis 54 PsA 54 whooping cough pertussis 54 chlamydial 54 CBLC# 54 minimally symptomatic 54 Ceflatonin 54 drugs DMARDs 54 Romiplostim 54 Onrigin 54 atypical Hemolytic Uremic Syndrome 54 malignant gliomas 54 Sipuleucel T 54 vancomycin resistant 54 invasive aspergillosis 54 vimentin 54 Extensively drug 54 BCR ABL 54 lung adenocarcinomas 54 cutaneous squamous cell carcinoma 54 hypomethylating agents 54 precancerous condition 54 anti TNF alpha 54 Amgen Neulasta ® 54 anticancer therapy 54 nucleoside analogue 54 immunomodulatory therapy 54 TKIs 54 recurrent glioblastoma 54 cytarabine daunorubicin 54 TTF Therapy 54 bortezomib refractory 54 Neovascular Age Related Macular 54 pneumococcal serotypes 54 acute lymphoblastic 54 temozolomide 54 Staphylococcus epidermidis 54 ganetespib 54 maximally tolerated lipid lowering 54 Parnate 54 CMV disease 54 intensive statin therapy 54 efalizumab 54 anakinra 54 relapsed myeloma 54 Metastatic Colorectal Cancer 54 TNF antagonist 54 immunomodulators 54 susceptible isolates 54 chronic myeloid leukemia 54 ara C 54 latent TB infection 54 fluvastatin 54 colorectal carcinomas 54 neratinib 54 severely active polyarticular 54 amphotericin 54 resistant ovarian cancer 54 adenovirus infections 54 rheumatoid arthritis psoriatic arthritis 54 herpesviruses 54 oncogenic HPV 54 S OIV 54 unresectable stage 54 pneumococcal bacteria 54 neovascular diseases 54 Tacrolimus 54 Azathioprine 54 systemic anaplastic large 54 colorectal liver metastases 53 dyskeratosis congenita 53 antibody mediated 53 tumor shrinkage 53 Pegintron 53 Rev Dex 53 H Pylori 53 Lupus Nephritis 53 leukotriene receptor antagonist 53 hypervirulent strain 53 dengue haemorrhagic fever DHF 53 SCIg 53 cediranib 53 Cerebral malaria 53 Advaxis Phase 53 chronic hepatitis B. 53 pegylated interferon peg IFN 53 Valortim R 53 NNRTI resistance 53 pDC 53 recurrent GBM 53 colorectal cancer liver metastases 53 5 Fluorouracil 53 OncoVex 53 latent tuberculosis infection 53 YONDELIS 53 Erlotinib 53 Cloretazine 53 HGS ETR2 53 idiopathic PAH 53 lapatinib Tykerb 53 Smac mimetics 53 FOLFIRI 53 Tarceva erlotinib 53 pancreatic NET 53 ankylosing spondylitis AS 53 Platinol ® 53 Decitabine 53 acute leukemias 53 Multidrug resistant TB 53 acute lymphoid leukemia 53 tipifarnib 53 refractory indolent non 53 glioblastoma brain tumor 53 systemic juvenile idiopathic 53 cell lymphoma ALCL 53 weekly subcutaneous injections 53 pegylated interferons 53 Ontak 53 HCV protease inhibitors 53 Herpes virus 53 letrozole Femara 53 Teriflunomide 53 hormone refractory 53 Ceplene/IL-2 53 Cell Non Hodgkin 53 enzastaurin 53 isoniazid 53 Pneumococcal pneumonia 53 mucocutaneous reactions 53 seronegative 53 echinocandins 53 advanced adenomas 53 xenograft models 53 mTOR inhibitor 53 olanzapine Zyprexa 53 immunocompromised mice 53 amantadine Symmetrel 53 oropharyngeal candidiasis OPC 53 oral clodronate 53 non metastatic osteosarcoma 53 alvespimycin 53 bortezomib 53 subependymal giant cell 53 feline distemper 53 follicular lymphoma FL 53 androgen independent 53 B CLL 53 VEGF inhibitors 53 peptide antigens 53 IgG antibodies 53 Adjuvant chemotherapy 53 peginterferon alfa 2a Pegasys 53 delayed onset CINV 53 Elvitegravir 53 azacitidine 53 multitargeted 53 PD LID 53 haematological malignancies 53 inhibit replication 53 haematologic malignancies 53 carbapenem antibiotics 53 amphotericin B 53 Iressa gefitinib 53 lymphoblastic leukemia 53 Soft Tissue Sarcoma 53 methicillin susceptible Staphylococcus aureus 53 S. aureus bacteremia 53 Canine influenza 53 Cabazitaxel 53 Tindamax R 53 adefovir 53 advanced NSCLC 53 dengue hemorrhagic fever DHF 53 Metastatic melanoma 53 Navelbine ® 53 systemic fungal infections 53 Chronic Hepatitis C 53 cell carcinoma RCC 53 Hypotension 53 sorafenib Nexavar 53 Cell Lymphoma CTCL 53 non nucleoside HCV 53 experimental autoimmune encephalomyelitis 53 Japanese Encephalitis virus 53 carbapenem resistant Klebsiella pneumoniae 53 serious pneumococcal infections 53 Trastuzumab